BMRN vs NBIX
BMRN: BioMarin is a global rare disease biotech company delivering genetic medicines across enzyme therapies, growth disorders, metabolic diseases, and gene therapies with a proven $3.2 billion commercial franchise. NBIX: Neurocrine is a profitably growing, neuroscience-focused biotech commercializing novel treatments for movement disorders, endocrine diseases, and psychiatric conditions with expanding late-stage pipeline and recent M&A.
Side-by-side fundamentals
| Metric | BMRN | NBIX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $58.40 | $172.69 | |
| Market cap as of 2026-07-23 | $11.3B | $17.8B | |
| P/E as of 2026-07-23 | 42.00 | 26.70 | NBIX lower |
| PEG as of 2026-07-23 | n/a | 0.23 | |
| Net margin as of 2026-07-23 | +8.3% | +21.6% | NBIX higher |
| Gross margin as of 2026-07-23 | +80.2% | +98.2% | NBIX higher |
| Operating margin as of 2026-07-23 | +9.7% | +25.4% | NBIX higher |
| ROE as of 2026-07-23 | +4.4% | +21.6% | NBIX higher |
| ROA as of 2026-07-23 | +3.4% | +15.1% | NBIX higher |
| Debt / equity as of 2026-07-23 | 0.23 | 0.00 | NBIX lower |
| Revenue growth (YoY) as of 2026-07-23 | +9.9% | +28.6% | NBIX higher |
| Revenue CAGR (3y) SEC XBRL | +15.4% | +24.3% | NBIX higher |
| Beta as of 2026-07-23 | 0.23 | 0.39 | |
| 1-year return as of 2026-07-22 close | -1.4% | +30.1% | NBIX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.